hVIVO (LON:HVO) Stock Price Up 10% – Still a Buy?

hVIVO plc (LON:HVO)’s stock price was up 10% during mid-day trading on Tuesday . The stock traded as high as GBX 22 ($0.27) and last traded at GBX 21.25 ($0.26). Approximately 7,804,669 shares changed hands during mid-day trading, an increase of 164% from the average daily volume of 2,961,263 shares. The stock had previously closed at GBX 19.33 ($0.24).

hVIVO Trading Down 2.1 %

The company has a market cap of £140.53 million, a price-to-earnings ratio of 688.50 and a beta of 0.97. The business has a fifty day simple moving average of GBX 20.25 and a 200 day simple moving average of GBX 25.68. The company has a quick ratio of 1.16, a current ratio of 1.61 and a debt-to-equity ratio of 33.86.

hVIVO Company Profile

hVIVO plc operates as a pharmaceutical service and contract research company. The company is involved in testing vaccines and antivirals using human challenge clinical trials. It provides services to big pharma, biotech, government, and public health organizations. The company has a portfolio of human challenge study models for conditions, such as RSV, flu, human rhinovirus, asthma, malaria, cough, and COPD, as well as developing COVID-19 human challenge study model.